NovaBridge Biosciences (NBP) Total Liabilities (2017 - 2025)

NovaBridge Biosciences (NBP) has 9 years of Total Liabilities data on file, last reported at $29.6 million in Q4 2025.

• Total Liabilities for Q4 2025 came in at $29.6 million, up 156.78% year-over-year; the trailing twelve-month figure through Dec 2025 was $29.6 million (up 156.78% YoY), and the FY2025 annual result was $29.6 million, up 156.78% from the prior year.
• Total Liabilities grew to $29.6 million in Q4 2025 per NBP's latest filing, from $18.5 million in the prior quarter.
• Over five years, Total Liabilities peaked at $163.6 million in Q4 2022 and troughed at $10.0 million in Q2 2025.
• A 5-year average of $74.0 million and a median of $29.6 million in 2025 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities slumped 90.73% in 2024, then surged 156.78% in 2025.
• A 5-year view of Total Liabilities shows it stood at $162.9 million in 2021, then rose by 0.43% to $163.6 million in 2022, then dropped by 24.05% to $124.3 million in 2023, then slumped by 90.73% to $11.5 million in 2024, then jumped by 156.78% to $29.6 million in 2025.
• Business Quant data shows NBP's Total Liabilities at $29.6 million in Q4 2025, $18.5 million in Q3 2025, and $10.0 million in Q2 2025.